RNU6-889P

Across TCGA pan-cancer cohorts, RNU6-889P RNA is linked to patient survival in 7 of 34 cancer types, making it the most broadly survival-associated RNU6-889P data layer.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher RNU6-889P RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RNU6-889P expression acts as an unfavorable survival marker.

BLCA, THYM, and LAML are the cancer types where RNU6-889P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Tertile	All	0.156	0.617	.001	54	view →
THYM	OS	Tertile	All	0.186	0.931	<.001	45	view →
LAML	DFS	Tertile	All	0.111	0.572	.010	36	view →
LUSC	OS	Tertile	III,IV	0.054	0.768	<.001	36	view →
LGG	DFS	Tertile	All	0.162	0.760	<.001	36	view →
SARC	OS	Tertile	All	0.022	0.861	<.001	36	view →
BRCA	OS	Tertile	All	0.188	0.580	.025	12	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

RNU6-889P–BLCA (DFS)

Open the BLCA breakdown →